Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer:Chemotherapy or Chemoradiotherapy?
| Autor: | Eva Versteijne, Ignace H. J. T. de Hingh, Marjolein Y. V. Homs, Martijn P. W. Intven, Joost M. Klaase, Hjalmar C. van Santvoort, Judith de Vos-Geelen, Johanna W. Wilmink, Geertjan van Tienhoven |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
neoadjuvant treatment
Cancer Research RESECTION borderline resectable pancreatic cancer (BRPC) MULTICENTER Neoplasms. Tumors. Oncology. Including cancer and carcinogens DUCTAL ADENOCARCINOMA CONCURRENT RADIATION OPEN-LABEL chemotherapy UPFRONT SURGERY THERAPY CHEMORADIATION ADJUVANT CHEMOTHERAPY Oncology SDG 3 - Good Health and Well-being FULL-DOSE GEMCITABINE resectable pancreatic cancer (RPC) radiotherapy RC254-282 |
| Zdroj: | Versteijne, E, de Hingh, I H J T, Homs, M Y V, Intven, M P W, Klaase, J M, van Santvoort, H C, de Vos-Geelen, J, Wilmink, J W & van Tienhoven, G 2022, ' Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer : Chemotherapy or Chemoradiotherapy? ', Frontiers in Oncology, vol. 11, 744161 . https://doi.org/10.3389/fonc.2021.744161 Frontiers in Oncology, Vol 11 (2022) |
| DOI: | 10.3389/fonc.2021.744161 |
| Popis: | Worldwide, there is a shifting paradigm from immediate surgery with adjuvant treatment to a neoadjuvant approach for patients with resectable or borderline resectable pancreatic cancer (RPC or BRPC). Comparison of neoadjuvant and adjuvant studies is extremely difficult because of a great difference in patient selection. The evidence from randomized studies shows that overall survival by intention-to-treat improves after neoadjuvant gemcitabine-based chemoradiotherapy or chemotherapy (various regimens), as compared to immediate surgery followed by adjuvant chemotherapy. Radiotherapy appears to play an important role in mediating locoregional effects. Yet, since more effective chemotherapy regimens are currently available, in particular FOLFIRINOX and Gemcitabine/Nab-paclitaxel, these chemotherapy regimens should be investigated in future randomized trials combined with (stereotactic) radiotherapy to further improve outcomes of RPC and BRPC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|